此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children

2014年7月21日 更新者:MedImmune LLC

A Post Marketing Evaluation of the Effectiveness of the Risk Minimization Plan For Use of FluMist Among Children Less Than 5 Years of Age

This is a retrospective cohort study of children included in a large medical insurance claims database.

研究概览

地位

完全的

详细说明

  • To evaluate the rate of FluMist administration compared to other influenza vaccine use in the following pediatric populations:

    • Children younger than 24 months of age
    • Children 24-59 months of age with a claim associated with a diagnosis of asthma
    • Children 24-59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
    • Children 24-59 months of age with immunosuppression
  • To describe, in children in the above populations who receive FluMist, the type and number of Emergency Room visits or hospitalizations associated with an insurance claim within 42 days of receiving FluMist
  • To explore the rationale for FluMist immunization of pediatric populations that are excluded from recommended usage by characterizing the use in these populations

研究类型

观察性的

注册 (实际的)

321697

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • North Carolina
      • Research Triangle、North Carolina、美国
        • Research Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Children < 60 months of age.

描述

  • Children less than 24 months of age during August through January/February.
  • Children <24 to 59 months of age during August through January/February, with:

    • two outpatient claims for asthma, or
    • one inpatient/emergency room claim for asthma, or
    • one outpatient claim for asthma and at least one SABA prescription during a defined 12-month period.
  • Children <24 to 59 months of age during August through January/February, without any claims associated with a diagnosis of asthma, but with at least one dispensing for SABA, as indicated by pharmacy claims during a defined 12-month period.
  • Children 24 to 59 months of age during August to January/February with evidence of immunosuppression prior to the date of influenza vaccination based on available medical and pharmacy claims.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:队列
  • 时间观点:追溯

队列和干预

团体/队列
干预/治疗
1
Children less than 24 months of age
There were no interventions. No subjects were enrolled in this retrospective database study.
2
Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
There were no interventions. No subjects were enrolled in this retrospective database study.
3
Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
There were no interventions. No subjects were enrolled in this retrospective database study.
4
Children 24-59 months of age with immunosuppression
There were no interventions. No subjects were enrolled in this retrospective database study.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
FluMist Use in Participants up to 59 Months of Age
大体时间:2009-2010
Among participants up to 59 months of age who received any flu vaccine, number who received FluMist
2009-2010
Vaccinating Physician Specialty: Pediatrician or Pediatric Specialist
大体时间:2009-2010
Specialty of vaccinating physician who provided FluMist.
2009-2010
Vaccinating Physician Specialty: General/Family Practitioner
大体时间:2009-2010
Specialty of vaccinating physician who provided FluMist
2009-2010
Vaccinating Physician Specialty: Other
大体时间:2009-2010
Specialty of vaccinating physician who provided FluMist
2009-2010
Vaccinating Physician Specialty: Unknown
大体时间:2009-2010
Specialty of vaccinating physician who provided FluMist
2009-2010
Geographic Region: Northeastern
大体时间:2009-2010
Geographic region of parents' residence among participants receiving FluMist
2009-2010
Geographic Region: North Central
大体时间:2009-2010
Geographic region of parents' residence among participants receiving FluMist
2009-2010
Geographic Region: Southern
大体时间:2009-2010
Geographic region of parents' residence among participants receiving FluMist
2009-2010
Geographic Region: Western
大体时间:2009-2010
Geographic region of parents' residence among participants receiving FluMist
2009-2010
Number of Outpatient Visits: 0
大体时间:2009-2010
Among participants vaccinated with FluMist, the number who had 0 outpatient visits in the 3 months prior to vaccination
2009-2010
Number of Outpatient Visits: 1
大体时间:2009-2010
Among participants vaccinated with FluMist, the number who had 1 outpatient visit in the 3 months prior to vaccination
2009-2010
Number of Outpatient Visits: 2 or More
大体时间:2009-2010
Among participants vaccinated with FluMist, the number who had 2 or more outpatient visits in the 3 months prior to vaccination
2009-2010
Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 0
大体时间:2009-2010
Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.
2009-2010
Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 1
大体时间:2009-2010
Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.
2009-2010
Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 2 or More
大体时间:2009-2010
Among participants vaccinated with FluMist, the number of days with a respiratory claim (asthma, acute respiratory distress, bronchospasm, influenza, respiratory syncytial virus, bronchiolitis, bronchitis, pneumonia, croup, sinusitis, adenovirus infection, coxsackie virus infection, rhinovirus infection, nasopharyngitis, laryngitis and tracheitis, upper respiratory infection, cough) in the 28 days prior to vaccination.
2009-2010

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 研究主任:Chris Ambrose, M.D.、MedImmune LLC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2007年10月1日

初级完成 (实际的)

2010年3月1日

研究完成 (实际的)

2010年3月1日

研究注册日期

首次提交

2008年2月20日

首先提交符合 QC 标准的

2008年2月20日

首次发布 (估计)

2008年2月29日

研究记录更新

最后更新发布 (估计)

2014年8月12日

上次提交的符合 QC 标准的更新

2014年7月21日

最后验证

2014年7月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • MI-MA175

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅